secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016633
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q2 net loss $34.1M; cuts 18 jobs, saves $40-50M, cash into mid-2024
--------------------------------------------------------------------------------

- Net loss $34.1M ($0.65 per share) vs $19.6M in Q2 2021; cash $169M as of June 30.
- Workforce reduction of 18 positions (~25% of planned headcount) primarily in discovery, research, and G&A.
- Expects ~$40-50M operating expense savings fully realized by mid-2024; cash runway extended into mid-2024.
- Phase 1b data for FTX-6058 in SCD showed HbF increases up to 6.3%; first patient enrolled in Phase 3 REACH trial for losmapimod in FSHD.
- Promoted Mel Hayes to COO and Curt Oltmans to Chief Legal Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017022016633/0000950170-22-016633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017022016633/fulc-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer